Status:
COMPLETED
Low-dose Albumin Infusion for the Prevention of Paracentesis Induced Circulatory Dysfunction (PICD), After Large Volume Paracentesis (LVP) in Decompensated Cirrhosis Liver.
Lead Sponsor:
Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
Conditions:
Paracentesis-Induced Circulatory Dysfunction
Eligibility:
All Genders
18-80 years
Phase:
PHASE4
Brief Summary
Abstract for thesis protocol. Background: Paracentesis induced circulatory dysfunction (PICD) is a common complication of large volume paracentesis in cirrhotic patients, which can lead to renal impai...
Detailed Description
Introduction. Cirrhosis of liver is the almost final pathway of chronic liver disease, leading to hepatocellular carcinoma that become critical when it progress to decompensation, denotes 13th most co...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Cirrhotic patients with grade-III ascites.
- Age 18 to 80 years.
- Willing to consent for clinical trial.
- Exclusion criteria:
- Acute liver failure.
- Impaired consciousness.
- Patients with following concomitant diseases,
- Severe cardiac diseases, respiratory diseases, and Renal impairment, (S. Creatinine \>1.5 mg/dl).
- Hyponatremia.
- Advanced HCC (\>3 nodule, portal vein thrombosis)
- Hepatic encephalopathy,
- Sepsis,
- Recent bleeding, e.g., GIT hemorrhage within 7 days before study.
- Pregnancy.
- Unable or not willing to consent for clinical trial.
Exclusion
Key Trial Info
Start Date :
February 2 2024
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 28 2025
Estimated Enrollment :
52 Patients enrolled
Trial Details
Trial ID
NCT06892535
Start Date
February 2 2024
End Date
February 28 2025
Last Update
March 24 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Hepatology, Bangabandhu Sheikh Mujib Medical University. Dhaka, Bangladesh.
Dhaka, Shahbag, Bangladesh, 1000